Lapatinib as a small molecule inhibitor of HER2, has been developed to expand the options for treating HER‐positive breast cancer.[69] Further, we found that the combined usage of etomoxir (50 μm) and lapatinib significantly decreased the cell viability of BT‐474 cells than that using lapatinib alone (Figure 7L). The gene discussed is ERBB2; the disease is breast cancer.